| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Mayo Clinic-led research supports an optimized diagnostic approach that incorporates autoantibody profiles to screen for and confirm presence of myasthenia gravis (MG) and Lambert-Eaton syndrome (LES).
Our first-line MG and LES evaluation examines levels of acetylcholine receptor binding antibodies (AChR-Bi). Utilizing a unique human muscle reagent, in which live cells mimic the neuromuscular junction where antibody interaction occurs, this test enables the highest testing sensitivity by providing the lowest cut-off values of receptor binding antibodies. If positive, confirmatory testing measures levels of acetylcholine receptor modulating antibodies (AChR-Mo). In cases where AChR-Bi antibodies are not found, testing automatically reflexes to muscle-specific kinase (MuSK) antibody testing.
95%
95% specificity
90%
90% sensitivity
45%
45% fewer false positives
Myasthenia gravis and Lambert-Eaton syndrome Test menu
Key testing
Advantages
Highlights
Advanced testing at Mayo Clinic Laboratories that confirmed a diagnosis of myasthenia gravis put Lorinda McKinley on the road to renewed health after she nearly lost it all to the rare autoimmune disease.
Christopher Klein, M.D., discusses Mayo Clinic’s updated myasthenia gravis and Lambert-Eaton syndrome testing approach. Automatic reflex to second-line testing saves time and increases sensitivity and specificity to confirm diagnosis in patients with atypical presentation.